Researchers have done this study in Denmark. They have implanted the device containing bone building drugs in 7 older women of ages 65-70 and found that the drug delivery was same as that after injections. The device delivered the drug for 20 days.
They have published this finding in the journal of Science Translational Medicine.
"These data validate the microchip approach to multi-year drug delivery without the need for frequent injections, which can improve the management of many chronic diseases like osteoporosis where adherence to therapy is a significant problem," said study lead author Robert Farra, MicroCHIPS President and Chief Operating Officer. "We look forward to making further progress to advance our first device toward regulatory approvals, as well as developing a range of products for use in important disease areas such as osteoporosis, cardiovascular disease, multiple sclerosis, cancer, and chronic pain."